Self-Treat Vagus Nerve Stimulator Shows Promise For Cluster Headaches
This article was originally published in The Gray Sheet
Executive Summary
A one-year open-label study published in Neurology suggests that electroCore’s gammaCore non-invasive vagus nerve stimulation system could be a practical therapy for chronic cluster headaches.
You may also be interested in...
ElectroCore Aims To Bring Neurostimulation To The Masses, Beginning With Headache
Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.